Document is current
Any future updates will be listed below
-
Authors
Lee, Richard W. https://orcid.org/0000-0001-8368-3406
Nair, Arjun
Balata, Haval
Graham, Charlotte
Parylo, Craig https://orcid.org/0000-0003-4297-7808
Abell, Jessica https://orcid.org/0000-0002-2125-2229
Woodall, Michael
Lawrie, Michael https://orcid.org/0000-0002-0389-4017
Mouland, Sally
Brain, Kate
Clark, Michelle
Crosbie, Philip
Devaraj, Anand
Fox, Jesme
Grange, Martin
Janes, Sam M. https://orcid.org/0000-0002-6634-5939
Johnson, Peter https://orcid.org/0000-0003-2306-4974
Mackie, Anne
Navani, Neal https://orcid.org/0000-0002-6412-7516
Quaife, Samantha L.
Randle, Amelia
Rawlinson, Janette https://orcid.org/0000-0002-9536-9809
Rintoul, Robert C. https://orcid.org/0000-0003-3875-3780
Rochelle, Liz
Sasieni, Peter https://orcid.org/0000-0003-1509-8744
Callister, Matthew E. J. https://orcid.org/0000-0001-8157-0803
Baldwin, David R. https://orcid.org/0000-0001-8410-7160
,
Akhurst, Ellis
Azam, Asif
Bartholomeuz, Thilan Rajith
Baugh, Stuart
Bibby, Anna
Booton, Richard
Brindle, Richard
Cheyne, Leanne
Daneshvar, Cyrus
Desai, Dhananjay
Dickson, Jennifer Lisa
Dosanjh, Gurnak Singh
Faccenda, Jacqueline
Fuller, Elizabeth Ruth
Gallardo, Matt Gabriel
Gill, Sindy
Graves, Jennifer
Grundy, Seamus
Hale, Christopher
Hicks, Alexander
Howells, John
Hume, Ian
Ledson, Martin
Low, Kai En
Mackinlay, Carolyn
Madathil, Afsar
Mahadevan, Venkateswaran
McMaster, Nicola
McSwiney, Stephen
Messenger, Jenny
Min, Carol
Mohamed, Peer Mohamad
Naidu, Babu
Nimako, Kofi
Page, Jason
Poole, Jason
Powell, Helen
Prasad, Baiju Saradananda
Rajasekaran, Arvind
Richards, Poppy
Randhawa, Rabinder Singh
Ryanna, Kimuli
Smith, Charlotte
Sridhar, Haarini
Taylor, Rebecca
Uys, Stephanie
Walsham, Anna C.
Warburton, Christopher James
Ward, Ann
Weatherhead, Mark
Windle, Tim
-
Funding
Funding for this research was provided by:
DH | National Institute for Health Research (N/A)
- License Information
-
More Information
Article History
Received: 1 September 2025
Accepted: 16 February 2026
First Online: 23 March 2026
Competing interests
: H.B. reports honoraria or institutional funding for nonpromotional educational talks or advisory boards from Intuitive Surgical, AMBU, Verathon, ESMO, NICE and OncLive, as well as paid proctorship work with Intuitive Surgical. M.G. has served as a member of the NHS England Screening Advisory Group, the chair of trustees for the British Thoracic Oncology Group and UK Lung Cancer Coalition as a trustee for the Roy Castle Lung Cancer Foundation. R.W.L. is funded by the Royal Marsden NIHR Biomedical Research Centre (BRC) and the Royal Marsden Cancer Charity. R.W.L.’s institution receives compensation for time spent in a secondment role for the NHS England Lung Health Check program and previously as National Specialty Lead for the NIHR. He has received research funding from Cancer Research UK (CRUK), Innovate UK (cofunded by GE HealthCare, Roche Diagnostics, Optellum, Elliptica and RNA Guardian) and SBRI Healthcare (including as a co-applicant with QURE.AI), RM Partners Cancer Alliance and NIHR (including co-applicant in grants with Optellum). He has received honoraria, speaker/advisory fees, and hospitality/travel expenses from CRUK, Roche Diagnostics, Johnson & Johnson, Guardant, AstraZeneca and King Faisal Hospital, Saudi Arabia. He also undertakes medical private practice. S.L.Q. is supported by Barts Charity (G-001522, MGU0461) and declares grant income from the NIHR, National Institutes of Health, Yorkshire Cancer Research and CRUK. R.C.R. is funded by Cambridge NIHR BRC (NIHR203312) and CRUK (Cambridge Centre CTRQQR-2021/100012). He receives research funding from CRUK, UKRI Medical Research Council (MRC), and Asthma and Lung UK. He is a director of and clinical lead for the UK Lung Cancer Coalition. He is a clinical director for the Cambridge and Peterborough Integrated Care System (ICS) Lung Cancer Screening Programme. N.N. is supported by an MRC Clinical Academic Research Partnership (MR/T02481X/1). This work was partly undertaken at University College London Hospitals and University College London, which received a proportion of funding from the Department of Health’s NIHR BRC funding scheme. He has received research funding from the NIHR, CRUK, SBRI, UKRI and the Ruth Strauss Foundation. N.N. reports honoraria or institutional funding for nonpromotional educational talks or advisory boards from Amgen, AstraZeneca, AXANA, Boehringer Ingelheim, Bristol Myers Squibb, EQRx, Fujifilm, Guardant Health, Intuitive, Janssen, Lilly, Merck Sharp & Dohme, Olympus, Roche and Sanofi. S.M.J. has received grant income from GRAIL Inc. He is an unpaid member of a GRAIL advisory board. He has received lecture fees for academic meetings from AstraZeneca. His wife works for AstraZeneca. The SUMMIT study is funded by GRAIL through a research grant awarded to S.M.J. as principal investigator. S.M.J. is supported by CRUK program grant no. EDDCPGM/100002 and an MRC program grant (MR/W025051/1/MRC), the Rosetrees Trust, the Roy Castle Lung Cancer foundation, the Garfield Weston Trust and the UCLH Charitable Foundation. A.R. declares consulting fees from Roche. J.R. was a member of the NHS England screening advisory group and is a member of the UK LC clinical expert group, British Thoracic Oncology Group steering committee, the ELF/ERS LC task forces and screening groups, the European Organisation for Research and Treatment of Cancer LC group and patient panel, the Cancer research advocates forum, the UCL lung cancer patient and public involvement (PPI) group, the Oxford cancer PPI group, the WM Cancer Alliance LC EAG and advocates’ EAG and BSOL ICS Targeted Lung Health Check working group. She is involved in PPI in several LC studies including PERFormance Evaluation for CT Screening (Nottingham), Lung Impact, DART and DOLCE, which use several industry software programs and tools for lung imaging, including Optellum and QURE AI. She has received occasional honoraria/travel expenses for LC screening meetings in the UK and Europe. D.R.B. declares grant income from Innovate UK, CRUK, SBRI and Horizon, and lecture honoraria from Boehringer Ingelheim and AstraZeneca. P.C. declares grant income from the NIHR, CRUK, Innovate UK, Yorkshire Cancer Research and Greater Manchester Cancer Alliance, consulting fees from Roche and honoraria from Bayer and Novartis. A.D. reports consulting fees from Boehringer Ingelheim, Roche, AstraZeneca and stocks interests in Brainomix. The other authors declare no competing interests.
